Jakheal 5 Tablet contains Tofacitinib 5mg, a Janus kinase (JAK) inhibitor used in the management of various autoimmune and inflammatory conditions. Tofacitinib works by selectively inhibiting JAK enzymes, which play a crucial role in the signaling pathways involved in the immune response. By modulating these pathways, Jakheal 5 helps reduce inflammation and immune system overactivity. It is commonly prescribed for the treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in patients who have had an inadequate response or intolerance to conventional therapies. The recommended dosage and duration of treatment should be determined by a healthcare professional based on the patient's condition and response to therapy. Patients should be monitored regularly for potential adverse effects, including infections, changes in blood counts, liver enzyme abnormalities, and lipid profile alterations. Jakheal 5 is contraindicated in patients with active infections, severe hepatic impairment, or known hypersensitivity to Tofacitinib. Caution is advised in patients with a history of malignancy or cardiovascular disease. It is essential to follow the prescribed dosage and consult a healthcare provider before initiating or discontinuing therapy.